中国急性ST段抬高型心肌梗死的临床管理(6)
[35] Montalescot G， van 't Hof AW， Lapostolle F， et al. ATLANTIC Investigators. Prehospital ticagrelor in ST-segment elevation myocardial infarction[J]. N Engl J Med， 2014，371：1016-1027.
[36] Valgimigli M， Frigoli E， Leonardi S， et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX)： final 1-year results of a multicenter， randomized controlled trial[J]. Lancet， 2018， 392：835-848.
[37] Valgimigli M， Bueno R， Byrne RA， et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS： The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J， 2018， 39(3)：213-260.
[38] Ndrepepa G， Colleran R， Kastrati A. Reperfusion injury in ST-segment elevation myocardial infarction： the final frontier [J]. Coron Artery Dis， 2017， 28(3)：253-262.
[39] Chi HJ， Chen ML， Yang XC， et al. Progress in Therapies for myocardial ischemia reperfusion injury [J].Curr Drug Targets， 2017， 18(15)：1712-1721.
(收稿日期：2019-12-05)
(本文編辑：郑海农), 百拇医药(沈卫峰)
[36] Valgimigli M， Frigoli E， Leonardi S， et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX)： final 1-year results of a multicenter， randomized controlled trial[J]. Lancet， 2018， 392：835-848.
[37] Valgimigli M， Bueno R， Byrne RA， et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS： The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J， 2018， 39(3)：213-260.
[38] Ndrepepa G， Colleran R， Kastrati A. Reperfusion injury in ST-segment elevation myocardial infarction： the final frontier [J]. Coron Artery Dis， 2017， 28(3)：253-262.
[39] Chi HJ， Chen ML， Yang XC， et al. Progress in Therapies for myocardial ischemia reperfusion injury [J].Curr Drug Targets， 2017， 18(15)：1712-1721.
(收稿日期：2019-12-05)
(本文編辑：郑海农), 百拇医药(沈卫峰)